Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1142012

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of patients treated for mental health disorders in NHS facilities received (a) drugs, (b) psychological therapy, (c) mindfulness meditation and (d) a combination of such approaches in the latest period for which figures are available.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	282217
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The information requested is not collected centrally.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 09/09/2019 17:41:44 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	534 label Biography information for Chris Ruane

1142016

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Loneliness: Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what research his Department has (a) commissioned and (b) evaluated on the potential effect of loneliness and social isolation on recovery rates from (i) cardiovascular disease, (ii) cancer and (iii) mental health conditions.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	282221
answer	answer is ministerial correction date of answer 04/09/2019 answer text <p>The Department is investing over £1 billion a year in health research through the National Institute for Health Research (NIHR). The NIHR’s research programmes provide a flexible source of funding. Applications are welcome for research into any aspect of human health, including research on the potential effect of loneliness and social isolation on recovery from Cardiovascular disease, cancer and mental health conditions; it is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p>The NIHR funds a number of research projects exploring the potential effect of loneliness and social isolation on recovery rates from cardiovascular disease, cancer and mental health conditions. Studies range in their focus, from specific vulnerable groups such as the elderly, those with mental health conditions or learning disabilities to the wider impact of social isolation and loneliness on an individual’s physical and mental health and well-being. The NIHR is funding two large studies focussing on improving the quality of life for people with serious mental health conditions, for example a £2.7 million study which includes testing a targeted, intervention to expand social networks of patients with psychosis and a £3.95 million study on immersive virtual reality as a treatment to help individuals with schizophrenia safely and confidently enter everyday situations. A current trial is testing an intervention to improve the physical and mental health outcomes for people who may be isolated due to a range of physical, psychological and social factors. Other studies, whose primary focus is not loneliness or social isolation, explore the effects of these within a broader context, for example a current study is researching the specific late effects of chemotherapy (such as hearing loss) and the associate impact on quality of life, including social isolation.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 04/09/2019 16:05:43 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	534 label Biography information for Chris Ruane

1142017

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much the NHS has spent on (a) anti-depressant drugs and (b) mindfulness-based stress reduction therapy in each year for which data is available.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	282222
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Information on how much the National Health Service has spent on antidepressant drugs is not collected in the format requested.</p><p>Information on expenditure on mindfulness-based therapies provided through NHS Improving Access to Psychological Therapies services is not separately identifiable and cannot be provided.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 09/09/2019 18:08:33 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	534 label Biography information for Chris Ruane

1142018

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much the Government spent on research into (a) anti-depressant drug treatment and (b) mindfulness-based stress reduction therapy in the latest period for which figures are available.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	282223
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Department funds health and care research through the National Institute for Health Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including mental health. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. The NIHR is the largest funder of mental health research in the United Kingdom. It has considerable investments in translational, clinical and applied mental health research. NIHR investment in mental health research for 2017/18 was £74.8 million.</p><p>The latest spend figures for research on antidepressant drug treatment and mindfulness-based stress reduction therapy are as follows:</p><p>Antidepressant drugs:</p><p> </p><table><tbody><tr><td colspan="2"><p>Financial Expenditure</p></td></tr><tr><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>NIHR Programmes total spend</p></td><td><p>£2,558,406.14</p></td><td><p>£3,269,938.30</p></td></tr></tbody></table><p> </p><p>Mindfulness - based therapy</p><table><tbody><tr><td colspan="2"><p>Financial Expenditure</p></td></tr><tr><td><p>2017/18</p></td><td><p>2018/19</p></td></tr><tr><td><p>NIHR Programmes total spend</p></td><td><p>£206,648</p></td><td><p>£308,645.22</p></td></tr></tbody></table><p>It should be noted that the spend figure on antidepressants will include studies where anti-depressants are repurposed for use in treating other conditions or where an anti-depressant will be being compared to a non-pharmacological intervention.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 09/09/2019 16:09:58 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	534 label Biography information for Chris Ruane

1142019

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) efficacy and (b) cost of the use of (i) anti-depressant drugs and (ii) mindfulness-based stress reduction therapy and mindfulness cognitive behaviour therapy.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	282224
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Medicines and Healthcare products Regulatory Agency is responsible for the regulation of medicines used in the United Kingdom, including efficacy. Anti-depressant medicines licensed in the UK have been approved after robust supporting data has been submitted to demonstrate the quality, safety and efficacy of the product for the condition it is intended to treat. For a medicine to be licenced, the benefit to risk balance should be positive<em>. </em></p><p>The National Institute for Health and Care Excellence (NICE) examines evidence of clinical and cost effectiveness when providing guidelines and recommendations of treatment. Presently, mindfulness-based therapy is only recommended for the treatment of depression in adults. NICE pathways bring together everything NICE says on a topic. The pathway for depression, including antidepressant treatment, is available at the following link:</p><p><a href="https://pathways.nice.org.uk/pathways/depression" target="_blank">https://pathways.nice.org.uk/pathways/depression</a></p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 09/09/2019 17:28:21 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	534 label Biography information for Chris Ruane

1142040

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Migraines: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect on demand for NHS services of self-administering treatments for migraine.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	282432
answer	answer is ministerial correction date of answer 04/09/2019 answer text <p>No assessment has made of the potential effect on demand for National Health Service services of self-administering treatments for migraine.</p><p> </p><p>Many patients with migraine can be successfully supported and managed through routine primary and secondary care pain management services and through the use of over-the -counter medicines. However, it is important that patients with the most serious pain management issues are able to access specialist care.</p><p> </p><p>The National Institute for Health and Care Excellence guideline, ‘Headaches: Diagnosis and management of headaches in young people and adults’, published in 2012 and updated in 2015, sets out evidence based best practice for healthcare professionals in the care, treatment and support of people who suffer from migraines.</p><p> </p><p>The guideline includes specific information on the management of migraines to either stop or prevent attacks, such as the prescribing of medications including analgesics, triptans and anti-emetics (as recommended in NICE's guideline on headaches in over 12s).</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 282433 question first answered 04/09/2019 15:59:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4603 label Biography information for Preet Kaur Gill

1142041

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Migraines: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure migraine sufferers are being given the option of self-administered treatments.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	282433
answer	answer is ministerial correction date of answer 04/09/2019 answer text <p>No assessment has made of the potential effect on demand for National Health Service services of self-administering treatments for migraine.</p><p> </p><p>Many patients with migraine can be successfully supported and managed through routine primary and secondary care pain management services and through the use of over-the -counter medicines. However, it is important that patients with the most serious pain management issues are able to access specialist care.</p><p> </p><p>The National Institute for Health and Care Excellence guideline, ‘Headaches: Diagnosis and management of headaches in young people and adults’, published in 2012 and updated in 2015, sets out evidence based best practice for healthcare professionals in the care, treatment and support of people who suffer from migraines.</p><p> </p><p>The guideline includes specific information on the management of migraines to either stop or prevent attacks, such as the prescribing of medications including analgesics, triptans and anti-emetics (as recommended in NICE's guideline on headaches in over 12s).</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 282432 question first answered 04/09/2019 15:59:08 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4603 label Biography information for Preet Kaur Gill

1142045

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Sir Mike Richards of NHS England on workforce implications for the NHS workforce in supporting the Independent Review of National Cancer Screening Programmes.
tabling member constituency	North Warwickshire
tabling member printed	Craig Tracey
uin	282435
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 17:50:15 answering member 4380 label Biography information for Jo Churchill
tabling member	4509 label Biography information for Craig Tracey

1142056

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Advanced Therapy Medicinal Products
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage innovation in gene and cell therapies and ensure that such therapies reach those patients who will benefit from such therapies.
tabling member constituency	Wolverhampton South West
tabling member printed	Eleanor Smith
uin	282440
answer	answer is ministerial correction date of answer 06/09/2019 answer text <p>The United Kingdom is a global leader in providing access to pioneering cell and gene therapies for treating diseases such as cancer, cystic fibrosis, heart disease and diabetes. Indeed, 24% of developers of advanced therapy medicinal products in Europe are headquartered in the UK. Last year the National Health Service was the first health system in Europe to agree full access for a revolutionary new CAR-T treatment, representing one of the fastest funding approvals in the history of our health service.</p><p>Together with the Cell and Gene Therapy Catapult we have nine specialist hospitals delivering approved CAR-T therapies as well as three Advanced Therapy Treatment Centres across the UK. These centres have been assigned £30 million by UK Research and Innovation - including project funding and an Apprenticeship Training Scheme.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 06/09/2019 11:11:41 answering member 4380 label Biography information for Jo Churchill
tabling member	4609 label Biography information for Eleanor Smith

1142057

registered interest
date	25/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of NICE modifying its Single Technology Appraisal ICER thresholds to recognise the value of treatments for severe and rare conditions that are not put through NICE’s Highly Specialised Technology pathway.
tabling member constituency	Wolverhampton South West
tabling member printed	Eleanor Smith
uin	282441
answer	answer is ministerial correction date of answer 05/09/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently reviewing its technology appraisal and highly specialised technology evaluation methods. The methods review will include a review of a wide range of methods, including those relevant to severe and rare conditions.</p><p>The Voluntary Scheme for Branded Medicines Pricing and Access 2019 - an agreement between the Government and the Association of the British Pharmaceutical Industry - states that the standard cost effectiveness threshold used by NICE will be retained at the current range (£20,000 - £30,000 per Quality Adjusted Life Year).</p><p>In the current Single Technology Appraisal process there are several factors that may currently be considered by NICE committees when deliberating, including some that may affect the value of a treatment. NICE’s methods review will explore if these factors are still relevant for patients and the National Health Service, whether there is a need to modify the approach and whether any additional factors should be taken into account when making a recommendation on a technology.</p><p>The review will also consider other methods that are important for rare and severe conditions, including methods for measuring and valuing the health-related quality of life for people with rare diseases, dealing with uncertainty and sourcing different types of evidence. Proposals will be presented for six weeks of public consultation in the summer of 2020.</p><p>Furthermore, in parallel with the methods review, NICE is reviewing its highly specialised technologies topic selection criteria – to make them clearer, more specific, and more transparent and predictable.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/09/2019 14:57:57 answering member 4380 label Biography information for Jo Churchill
tabling member	4609 label Biography information for Eleanor Smith